Clinical Trial of Zero Self-Payment Heavy Ion Therapy for Lung Cancer Now Fully Launched​

As the first hospital in China to clinically apply a domestic heavy ion system and the only hospital globally operating two heavy ion systems, Gansu Wuwei Cancer Hospital has accumulated five years of clinical experience, treating over 2,000 patients across more than 50 conditions, including lung cancer, pancreatic cancer, and liver cancer. Clinical efficacy and patient survival rates have reached internationally advanced levels. The hospital has achieved "eight world and domestic firsts": the only hospital globally operating two heavy ion therapy systems; the hospital with the highest number of single-fraction treatments completed within one day; the first globally to develop precision heavy ion therapy under ventilator control; the first globally to implement bladder cancer treatment with precise bladder volume management; the first globally to perform single-session heavy ion therapy using surgically placed spacers between organs and tumors; the first in China to develop a 360° rotatable and adjustable ion therapy chair; the first globally to complete multiple cases of cardiac tumor treatment with heavy ions; and the first globally to integrate heavy ion therapy with comprehensive, lifelong physical and mental health management.

To further advance the high-quality development of heavy ion therapy in China, we are now launching the "Clinical Study on Radical Carbon Ion Radiotherapy Combined with EGFR-TKI for Early-Stage Lung Cancer" based on our previous achievements. This study aims to establish China's clinical treatment standards for lung cancer using heavy ion systems that meet international benchmarks, while pursuing better therapeutic outcomes for patients.

Clinical Study on Radical Carbon Ion Radiotherapy Combined with EGFR-TKI for Early-Stage Lung Cancer​

​​Study Objective​

This single-center, single-arm, prospective Phase II clinical trial will enroll 37 patients with stage IA-IIA lung adenocarcinoma harboring EGFR exon 19 deletion or exon 21 (L858R) mutation. The study will evaluate disease-free survival in patients receiving radical carbon ion radiotherapy for primary lung lesions combined with EGFR-TKI therapy, while assessing the safety of this combined targeted treatment approach.

Inclusion Criteria​

1. Age 18-70 years; histologically confirmed peripheral lung adenocarcinoma; clinical stage cT1-2N0M0 (UICC 8th edition); confirmed EGFR exon 19 deletion or exon 21 (L858R) mutation

2. No prior surgery, chemotherapy, or immunotherapy

3. No participation in other similar studies

4. Willingness to sign informed consent and comply with follow-up

Final eligibility will be determined by investigators based on the trial protocol.

Study Procedures​

1. Screening: Physical examination, imaging (CT/MRI/PET-CT) and laboratory tests after signing informed consent

2. Treatment: Carbon ion radiotherapy (60Gy RBE to primary tumor) combined with EGFR-TKI therapy

3. Follow-up: Regular check-ups at 1, 3, 6, and 12 months post-treatment, then biannually for 10 years

Patient Benefits

1. Research funding provided by the hospital to cover heavy ion therapy costs

2. Personalized treatment plan developed by a multidisciplinary expert team (MDT)

3. Close follow-up monitoring and provision of subsequent treatment plans

​​Contact Information

Wuwei Heavy Ion Center, Gansu Wuwei Cancer Hospital

   Zhang Yihe: +86 139 9350 8641

Lanzhou Heavy Ion Center, Gansu Wuwei Cancer Hospital

   Qi Ying: +86 139 9350 3180